Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary
Compounding Law; Health Care; Awareness of all Types of Compounding Issues;
Pharmacy Benefit Managers (PBMs), Outsourcing Facilities
Food and Drug Administration and Compliance Issues
Pharmacists and patients concerned about the impact of new regulations by the Louisiana Pharmacy Board wanted to know Thursday why limits are proposed for sales of specialty medicines directly to physicians.
Malcolm J. Broussard, the board’s executive director, fielded questions during a public hearing at the board’s meeting room. No board members were present.
Broussard said the impetus for limiting such sales to 10 percent of a compounding pharmacy’s patient-prescription business can be seen in the misery caused last year by contaminated medicines from a Massachusetts company.
Dozens of people across the nation died from fungal meningitis traced to the Massachusetts company’s products.
“We haven’t heard from a (Louisiana) pharmacy yet that this rule would put them out of business,” Broussard added.